These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 24289920)

  • 1. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.
    Yehoshua Z; de Amorim Garcia Filho CA; Nunes RP; Gregori G; Penha FM; Moshfeghi AA; Zhang K; Sadda S; Feuer W; Rosenfeld PJ
    Ophthalmology; 2014 Mar; 121(3):693-701. PubMed ID: 24289920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration.
    Garcia Filho CA; Yehoshua Z; Gregori G; Nunes RP; Penha FM; Moshfeghi AA; Zhang K; Feuer W; Rosenfeld PJ
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(1):18-31. PubMed ID: 24354307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
    Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
    Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
    Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
    Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Rosenfeld PJ; Dugel PU; Holz FG; Heier JS; Pearlman JA; Novack RL; Csaky KG; Koester JM; Gregory JK; Kubota R
    Ophthalmology; 2018 Oct; 125(10):1556-1567. PubMed ID: 29716784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
    Wykoff CC; Rosenfeld PJ; Waheed NK; Singh RP; Ronca N; Slakter JS; Staurenghi G; Monés J; Baumal CR; Saroj N; Metlapally R; Ribeiro R
    Ophthalmology; 2021 Sep; 128(9):1325-1336. PubMed ID: 33711380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
    Holekamp N; Wykoff CC; Schmitz-Valckenberg S; Monés J; Souied EH; Lin H; Rabena MD; Cantrell RA; Henry EC; Tang F; Swaminathan B; Martin J; Ferrara D; Staurenghi G
    Ophthalmology; 2020 Jun; 127(6):769-783. PubMed ID: 32081489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial.
    Kim BJ; Hunter A; Brucker AJ; Hahn P; Gehrs K; Patel A; Edwards AO; Li Y; Khurana RN; Nissim I; Daniel E; Grunwald J; Ying GS; Pistilli M; Maguire MG; Dunaief JL
    Ophthalmol Retina; 2020 Sep; 4(9):889-898. PubMed ID: 32418846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
    Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
    JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Human Central Nervous System Stem Cell Subretinal Transplantation on Progression of Geographic Atrophy Secondary to Nonneovascular Age-Related Macular Degeneration.
    Nittala MG; Uji A; Velaga SB; Hariri AH; Naor J; Birch DG; Spencer R; Leng T; Capela A; Tsukamoto A; Ip M; Sadda SR
    Ophthalmol Retina; 2021 Jan; 5(1):32-40. PubMed ID: 32562884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Geographic Atrophy Growth Rates Using Different Imaging Modalities in the COMPLETE Study.
    Yehoshua Z; de Amorim Garcia Filho CA; Nunes RP; Gregori G; Penha FM; Moshfeghi AA; Sadda S; Feuer W; Rosenfeld PJ
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):413-22. PubMed ID: 25970861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.
    Schütze C; Wedl M; Baumann B; Pircher M; Hitzenberger CK; Schmidt-Erfurth U
    Am J Ophthalmol; 2015 Jun; 159(6):1100-1114.e1. PubMed ID: 25769245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.
    Nittala MG; Metlapally R; Ip M; Chakravarthy U; Holz FG; Staurenghi G; Waheed N; Velaga SB; Lindenberg S; Karamat A; Koester J; Ribeiro R; Sadda S
    JAMA Ophthalmol; 2022 Mar; 140(3):243-249. PubMed ID: 35113137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials.
    Heier JS; Pieramici D; Chakravarthy U; Patel SS; Gupta S; Lotery A; Lad EM; Silverman D; Henry EC; Anderesi M; Tschosik EA; Gray S; Ferrara D; Guymer R;
    Ophthalmol Retina; 2020 Jul; 4(7):673-688. PubMed ID: 32199866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration.
    Pfau M; von der Emde L; de Sisternes L; Hallak JA; Leng T; Schmitz-Valckenberg S; Holz FG; Fleckenstein M; Rubin DL
    JAMA Ophthalmol; 2020 Oct; 138(10):1026-1034. PubMed ID: 32789526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
    Grunwald JE; Daniel E; Huang J; Ying GS; Maguire MG; Toth CA; Jaffe GJ; Fine SL; Blodi B; Klein ML; Martin AA; Hagstrom SA; Martin DF;
    Ophthalmology; 2014 Jan; 121(1):150-161. PubMed ID: 24084496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Xu L; Mrejen S; Jung JJ; Gallego-Pinazo R; Thompson D; Marsiglia M; Freund KB
    Retina; 2015 Feb; 35(2):176-86. PubMed ID: 25387047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic Atrophy Growth Is Strongly Related to Lesion Perimeter: Unifying Effects of Lesion Area, Number, and Circularity on Growth.
    Shen LL; Sun M; Ahluwalia A; Young BK; Park MM; Del Priore LV
    Ophthalmol Retina; 2021 Sep; 5(9):868-878. PubMed ID: 33307218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
    Garg A; Nanji K; Tai F; Phillips M; Zeraatkar D; Garg SJ; Sadda SR; Kaiser PK; Guymer RH; Sivaprasad S; Wykoff CC; Chaudhary V
    Surv Ophthalmol; 2024; 69(3):349-361. PubMed ID: 38008405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 Trial Evaluating Minocycline for Geographic Atrophy in Age-Related Macular Degeneration: A Nonrandomized Controlled Trial.
    Keenan TDL; Bailey C; Abraham M; Orndahl C; Menezes S; Bellur S; Arunachalam T; Kangale-Whitney C; Srinivas S; Karamat A; Nittala M; Cunningham D; Jeffrey BG; Wiley HE; Thavikulwat AT; Sadda S; Cukras CA; Chew EY; Wong WT
    JAMA Ophthalmol; 2024 Apr; 142(4):345-355. PubMed ID: 38483382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.